Nan Min-Lun, Wang Xue, Li Hai-Jun, Yu De-Hai, Sun Wen-Yi, Xu Hong-Mei, He Yu-Fang, Zhao Quan-Cheng
Institute of Phytochemistry, Jilin Academy of Chinese Medicine Sciences, Changchun, Jilin 130000, P.R. China.
College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin 130042, P.R. China.
Oncol Lett. 2019 Jan;17(1):630-637. doi: 10.3892/ol.2018.9616. Epub 2018 Oct 24.
In the present study, the functions and mechanisms of rotundic acid (RA) underlying its induction of apoptosis in caspase-3-transfected MCF-7 human breast cancer cells (Cas3-MCF-7 cells) were investigated. RA induced apoptosis in Cas3-MCF-7 cells more efficiently compared with that in MCF-7 cells transfected with control plasmid. The results from an MTT assay demonstrated that RA effectively inhibited Cas3-MCF-7 cell viability in a dose-dependent manner and induced cell apoptosis via caspase-3 activity within 12 to 48 h. Western blotting and fluorescence-activated cell sorting demonstrated that RA initiated Cas3-MCF-7 cell apoptosis via p53 activation. The silencing of the p53 gene in the Cas3-MCF-7 cell line led to decreased RA-induced Cas3-MCF-7 cell caspase-3 activity and cell apoptosis. Collectively, the results of the present study indicate that caspase-3 serves a critical function in rotundic acid-induced apoptosis, and suggest that caspase-3 deficiency may contribute to the chemotherapy-resistance of breast cancer. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to chemotherapy. RA has the potential for development as a novel drug combined with reconstitution of caspase-3 gene therapy for the treatment of human breast cancer with caspase-3 deficiency.
在本研究中,研究了圆二烯酸(RA)诱导半胱天冬酶-3转染的MCF-7人乳腺癌细胞(Cas3-MCF-7细胞)凋亡的功能及机制。与转染对照质粒的MCF-7细胞相比,RA更有效地诱导了Cas3-MCF-7细胞凋亡。MTT试验结果表明,RA以剂量依赖的方式有效抑制Cas3-MCF-7细胞活力,并在12至48小时内通过半胱天冬酶-3活性诱导细胞凋亡。蛋白质免疫印迹和荧光激活细胞分选表明,RA通过p53激活引发Cas3-MCF-7细胞凋亡。Cas3-MCF-7细胞系中p53基因的沉默导致RA诱导的Cas3-MCF-7细胞半胱天冬酶-3活性和细胞凋亡降低。总体而言,本研究结果表明半胱天冬酶-3在圆二烯酸诱导的凋亡中起关键作用,并提示半胱天冬酶-3缺陷可能导致乳腺癌的化疗耐药性。半胱天冬酶-3的重建使MCF-7乳腺癌细胞对化疗敏感。RA有潜力开发成为一种新型药物,与半胱天冬酶-3基因治疗重建相结合,用于治疗半胱天冬酶-3缺陷的人类乳腺癌。